Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts.

Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA.

Cancer Discov. 2019 Aug;9(8):1102-1123. doi: 10.1158/2159-8290.CD-19-0094. Epub 2019 Jun 13.

PMID:
31197017
2.

Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.

Blair AB, Kim VM, Muth ST, Saung MT, Lokker N, Blouw B, Armstrong TD, Jaffee EM, Tsujikawa T, Coussens LM, He J, Burkhart RA, Wolfgang CL, Zheng L.

Clin Cancer Res. 2019 Jun 11. doi: 10.1158/1078-0432.CCR-18-4192. [Epub ahead of print]

PMID:
31186314
3.

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.

Kim VM, Blair AB, Lauer P, Foley K, Che X, Soares K, Xia T, Muth ST, Kleponis J, Armstrong TD, Wolfgang CL, Jaffee EM, Brockstedt D, Zheng L.

J Immunother Cancer. 2019 May 22;7(1):132. doi: 10.1186/s40425-019-0601-5.

4.

Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.

Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, Woolman S, Armstrong TD, Connolly RM, Azad NA, Jaffee EM, Roussos Torres ET.

Cancer Immunol Res. 2018 Dec;6(12):1561-1577. doi: 10.1158/2326-6066.CIR-18-0070. Epub 2018 Oct 19.

PMID:
30341213
5.

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.

Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K, Woolman S, Vithayathil T, Glickman LH, Ndubaku CO, McWhirter SM, Dubensky TW Jr, Armstrong TD, Jaffee EM, Zaidi N.

JCI Insight. 2018 Oct 18;3(20). pii: 122857. doi: 10.1172/jci.insight.122857.

6.

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.

Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, Kanne DB, Jaffee EM, Dubensky TW Jr, Emens LA.

Cancer Immunol Res. 2017 Jun;5(6):468-479. doi: 10.1158/2326-6066.CIR-16-0284. Epub 2017 May 8.

7.

Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.

Sunay MM, Foote JB, Leatherman JM, Edwards JP, Armstrong TD, Nirschl CJ, Hicks J, Emens LA.

Int Immunopharmacol. 2017 May;46:112-123. doi: 10.1016/j.intimp.2017.02.028. Epub 2017 Mar 7.

8.

African-American Congregational Care and Counseling: Transcending Universal and Culturally-Specific Barriers.

Armstrong TD.

J Pastoral Care Counsel. 2016 Jun;70(2):118-22. doi: 10.1177/1542305016634666.

PMID:
27281758
9.

Special Conference on Tumor Immunology and Immunotherapy: A New Chapter.

Byrne KT, Vonderheide RH, Jaffee EM, Armstrong TD.

Cancer Immunol Res. 2015 Jun;3(6):590-597. doi: 10.1158/2326-6066.CIR-15-0106. Epub 2015 May 12.

10.

Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.

Chu NJ, Armstrong TD, Jaffee EM.

Clin Cancer Res. 2015 Apr 1;21(7):1549-57. doi: 10.1158/1078-0432.CCR-14-1186. Epub 2015 Jan 26. Review.

11.

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.

De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, Caturegli P.

Int J Cancer. 2015 Jan 1;136(1):127-37. doi: 10.1002/ijc.28973. Epub 2014 May 28.

12.

Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice.

Black CM, Armstrong TD, Jaffee EM.

Cancer Immunol Res. 2014 Apr;2(4):307-19. doi: 10.1158/2326-6066.CIR-13-0145. Epub 2014 Jan 17.

13.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM.

Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.

14.

Tumor immunology: multidisciplinary science driving basic and clinical advances.

Keenan BP, Jaffee EM, Armstrong TD.

Cancer Immunol Res. 2013 Jul;1(1):16-23.

15.

Targeting the right regulatory T-cell population for tumor immunotherapy.

Weiss VL, Lee TH, Jaffee EM, Armstrong TD.

Oncoimmunology. 2012 Oct 1;1(7):1191-1193.

16.

Circles of care: development and initial evaluation of a peer support model for African Americans with advanced cancer.

Hanson LC, Armstrong TD, Green MA, Hayes M, Peacock S, Elliot-Bynum S, Goldmon MV, Corbie-Smith G, Earp JA.

Health Educ Behav. 2013 Oct;40(5):536-43. doi: 10.1177/1090198112461252. Epub 2012 Oct 16.

17.

Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.

Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD.

PLoS One. 2012;7(2):e31962. doi: 10.1371/journal.pone.0031962. Epub 2012 Feb 16.

18.

Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.

Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM.

J Immunol. 2011 Apr 1;186(7):3847-57. doi: 10.4049/jimmunol.1000361. Epub 2011 Feb 23.

19.

CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.

Le DT, Ladle BH, Lee T, Weiss V, Yao X, Leubner A, Armstrong TD, Jaffee EM.

Int J Cancer. 2011 Aug 1;129(3):636-47. doi: 10.1002/ijc.25693. Epub 2010 Nov 12.

20.

Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.

Pfannenstiel LW, Lam SS, Emens LA, Jaffee EM, Armstrong TD.

Cell Immunol. 2010;263(1):79-87. doi: 10.1016/j.cellimm.2010.03.001. Epub 2010 Mar 6.

21.
22.

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S, Sgouros G, Emens LA, Reilly RT, Jaffee EM.

J Clin Invest. 2008 May;118(5):1700-11. doi: 10.1172/JCI34333.

23.

Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting.

Miyashita T, Shah FA, Marti GP, Armstrong TD, Wang J, Bonde P, Gibson MK, Yoshimura K, Montgomery EA, Duncan M, Jaffee EM, Harmon JW.

Dig Dis Sci. 2008 Nov;53(11):2858-67. doi: 10.1007/s10620-008-0232-z. Epub 2008 Mar 15.

PMID:
18343998
24.

Religion/Spirituality and adolescent psychiatric symptoms: a review.

Dew RE, Daniel SS, Armstrong TD, Goldston DB, Triplett MF, Koenig HG.

Child Psychiatry Hum Dev. 2008 Dec;39(4):381-98. doi: 10.1007/s10578-007-0093-2. Epub 2008 Jan 25. Review.

PMID:
18219572
25.

A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.

Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM, Emens LA.

Clin Cancer Res. 2007 Jul 1;13(13):3951-9.

26.

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, Reilly RT.

J Immunol. 2006 Jan 15;176(2):974-83.

27.

Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms.

Gandini S, Lowenfels AB, Jaffee EM, Armstrong TD, Maisonneuve P.

Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1908-16. Review.

28.

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.

Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM.

J Exp Med. 2005 May 16;201(10):1591-602. Epub 2005 May 9.

29.

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM.

J Exp Med. 2004 Aug 2;200(3):297-306.

30.

Cytokine modified tumor vaccines.

Armstrong TD, Jaffee EM.

Surg Oncol Clin N Am. 2002 Jul;11(3):681-96. Review.

PMID:
12487062
31.

Community studies on adolescent substance use, abuse, or dependence and psychiatric comorbidity.

Armstrong TD, Costello EJ.

J Consult Clin Psychol. 2002 Dec;70(6):1224-39. Review.

PMID:
12472299
32.

Prevalence of DSM-IV alcohol diagnoses and symptoms in adolescent community and clinical samples.

Chung T, Martin CS, Armstrong TD, Labouvie EW.

J Am Acad Child Adolesc Psychiatry. 2002 May;41(5):546-54.

PMID:
12014787
33.

Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines.

Ostrand-Rosenberg S, Pulaski BA, Armstrong TD, Clements VK.

Adv Exp Med Biol. 1998;451:259-64. No abstract available.

PMID:
10026883
34.
35.

Tumor antigen presentation: changing the rules.

Armstrong TD, Pulaski BA, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 1998 Apr;46(2):70-4. Review.

PMID:
9558001
36.

MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.

Armstrong TD, Clements VK, Ostrand-Rosenberg S.

J Immunol. 1998 Jan 15;160(2):661-6.

37.

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.

Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S.

Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91.

38.

Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.

Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S.

J Immunol. 1992 Oct 1;149(7):2391-6.

PMID:
1527384
39.

Group psychotherapy with deaf adolescents.

Bonham HE, Armstrong TD, Bonham GM.

Am Ann Deaf. 1981 Oct;126(7):806-9. No abstract available.

PMID:
7304375

Supplemental Content

Loading ...
Support Center